Thomas Zindrick
Amministratore Delegato presso GENELUX CORPORATION
Patrimonio netto: 48 641 $ in data 30/04/2024
Profilo
Thomas D.
Zindrick is currently the Chairman, President & Chief Executive Officer at Genelux Corp.
since 2010 and the Executive Vice Chairman at Aeromics, Inc. since 2018.
Previously, he served as the Director at DNX Biopharmaceuticals, Inc. from 2014 to 2020 and at Amitech Therapeutic Solutions, Inc. from 2011 to 2021.
He was also the Vice President & Associate General Counsel at Amgen, Inc. from 2008 to 2009.
Additionally, he worked as an Attorney at The Dow Chemical Co. Mr. Zindrick completed his undergraduate degree at North Central College and his graduate degree at the University of Illinois College of Law.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
GENELUX CORP.
0.05% | 26/03/2024 | 14 651 ( 0.05% ) | 48 641 $ | 30/04/2024 |
Posizioni attive di Thomas Zindrick
| Società | Posizione | Inizio |
|---|---|---|
| GENELUX CORPORATION | Amministratore Delegato | 28/05/2014 |
Aeromics, Inc.
 Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | Direttore/Membro del Consiglio | 16/08/2018 |
Precedenti posizioni note di Thomas Zindrick
| Società | Posizione | Fine |
|---|---|---|
| Amitech Therapeutic Solutions, Inc | Amministratore Delegato | 01/02/2021 |
DNX Biopharmaceuticals, Inc.
 DNX Biopharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services DNX Biopharmaceuticals, Inc. operates as a biopharmaceuticals company. It develops long-acting therapeutic proteins for the treatment of patients with life-long diseases. The company was founded by John Caputo, Rajiv Datar, and Howard Levine in 2014 and is headquartered in Irvine, CA. | Direttore/Membro del Consiglio | 01/03/2020 |
| AMGEN INC. | Responsabile della Conformità | 01/01/2008 |
| DOW CHEMICAL COMPANY (THE) | Corporate Officer/Principal | - |
Formazione di Thomas Zindrick
| North Central College | Undergraduate Degree |
| University of Illinois College of Law | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| GENELUX CORPORATION | Health Technology |
| Aziende private | 4 |
|---|---|
The Dow Chemical Co.
 The Dow Chemical Co. Chemicals: SpecialtyProcess Industries The Dow Chemical Co. engages in the manufacture and distribution of chemicals, plastics, industrial and agricultural products. It serves agriculture, automotive, building and construction, consumer, electronic materials, infrastructure, packaging, product finder and product safety industries. The company was founded by Herbert Henry Dow in 1897 and is headquartered in Midland, MI. | Process Industries |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | Health Technology |
DNX Biopharmaceuticals, Inc.
DNX Biopharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services DNX Biopharmaceuticals, Inc. operates as a biopharmaceuticals company. It develops long-acting therapeutic proteins for the treatment of patients with life-long diseases. The company was founded by John Caputo, Rajiv Datar, and Howard Levine in 2014 and is headquartered in Irvine, CA. | Commercial Services |
| Amitech Therapeutic Solutions, Inc |
- Borsa valori
- Insiders
- Thomas Zindrick
